Drug Profile
Ponatinib - Takeda
Alternative Names: AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; Iclusig; Ponatinib hydrochlorideLatest Information Update: 21 Feb 2019
Price :
$50
*
At a glance
- Originator ARIAD Pharmaceuticals
- Developer ARIAD Pharmaceuticals; Dana-Farber Cancer Institute; Massachusetts General Hospital; Mayo Clinic; National Cancer Institute (USA); Otsuka Pharmaceutical; University of Birmingham; University of Colorado at Denver
- Class Antineoplastics; Benzamides; Imidazoles; Piperazines; Pyridazines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase II Acute myeloid leukaemia; Biliary cancer; Gastrointestinal stromal tumours; Lung cancer; Squamous cell cancer; Thyroid cancer
- No development reported Solid tumours
Most Recent Events
- 01 May 2019 Incyte Biosciences plans a phase I/II trial for Solid tumours and Haematological malignancies (In childrens, Recurrent, Late-stage disease) in July 2019 (NCT03934372)
- 17 Jan 2019 Ariad Pharmaceuticals completes the phase II PACE trial for Chronic myeloid leukemia & Precursor-cell-lymphoblastic-leukaemia-lymphoma in Australia, Belgium, France, Germany, Italy, Netherlands, Singapore, South Korea, Spain, Sweden, United Kingdom (PO) (NCT01207440)
- 10 Sep 2018 Phase-III clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, First-line therapy) in USA (PO) (NCT03589326)